Navigation Links
Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Date:10/13/2009

Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorite des Marches Financiers.

[1] depending on the countries, Ipsen commercialises Decapeptyl(R) under different brand names (Diphereline(R), Pamorelin(R), Arvekap(R))

    [2] triptorelin pamoate is similar to triptorelin embonate

    For further information:

    Ipsen

    Media

    Didier Veron
    Director, Public Affairs and Corporate Communications
    Tel.: +33-(0)1-58-33-51-16
    Fax:  +33-(0)1-58-33-50-58
    E-mail: didier.veron@ipsen.com

    Financial Community

    David Schilansky
    Investor Relations and Financial Officer
    Tel.: +33-(0)1-58-33-51-30
    Fax:  +33-(0)1-58-33-50-63
    E-mail: david.schilansky@ipsen.com

    Pierre Kemula
    Investor Relations Manager
    Tel.: +33-(0)1-58-33-60-08
    Fax:  +33-(0)1-58-33-50-63
    E-mail: pierre.kemula@ipsen.com

    Debiopharm

    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs &
    Communication
    Tel.: +41-(0)21-321-01-11
    Fax:  +41-(0)21-321-01-69
  
'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
2. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
3. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
4. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
5. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
6. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Japanese Cancer Association and Debiopharm Honour Japanese Research
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. Debiopharm and EPFL Establish an Oncology Chair
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/s3s3t8/personalized ) ... report "Personalized Medicine - Scientific and Commercial ... The aim of personalized medicine or individualized ... the right patient and, in some cases, even ... according to his/her genotype. This report describes the ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. , ... viral vectors, nonviral vectors and cell therapy with ... method of drug delivery and various routes of ...
(Date:3/3/2015)... PHILADELPHIA , March 3, 2015 ... agencies with tools for implementing competency-based training to comply ... DirectCourse is offering a new crosswalk ... Services (HCBS) implement competency-based training for direct service workers ... Medicare & Medicaid Services (CMS) regulations. CMS ...
(Date:3/3/2015)... 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer ... focus on protecting the microbiome, announced today that Jeffrey ... the 27th Annual ROTH Conference being held on March 8-11, ... in Dana Point, CA. Mr. Riley ... 1:00 p.m. (Pacific Time). A live webcast of ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Milwaukee, Wis. - Rick Davidson jokes ... global is in your title, and your company operates in ... especially in jest. , ,Not that the good-humored Davidson, senior ... is prone to exaggeration. The Milwaukee-based employment services firm has ...
... ago, I had no idea that I would continue with it ... to share with other members of the Midwest life-science community information ... just overall awareness about life science in the Midwest. , ... I couldn't afford the kind of market research we used to ...
... Baird Venture Partners , the U.S. venture fund of ... presence in China by partnering with the Indian investment and ... as they establish a foothold in the Indian market. In ... Baird Venture Partners and director of Baird Private Equity Group, ...
Cached Biology Technology:CIO Leadership Series: Rick Davidson, Manpower 2CIO Leadership Series: Rick Davidson, Manpower 3CIO Leadership Series: Rick Davidson, Manpower 4CIO Leadership Series: Rick Davidson, Manpower 5A Midwest life-science odyssey comes full circle 2A Midwest life-science odyssey comes full circle 3A Midwest life-science odyssey comes full circle 4A Midwest life-science odyssey comes full circle 5A Midwest life-science odyssey comes full circle 6A Midwest life-science odyssey comes full circle 7A Midwest life-science odyssey comes full circle 8Visions: Carbone bullish on Wisconsin venture capital 2Visions: Carbone bullish on Wisconsin venture capital 3Visions: Carbone bullish on Wisconsin venture capital 4Visions: Carbone bullish on Wisconsin venture capital 5
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... , Technological advancements in medicine have allowed patients suffering ... to regain mobility and live relatively pain-free. But some ... the U.S. Food and Drug Administration (FDA) are not ... is tested to determine its safety and effectiveness. ...
... , Muscular dystrophy is caused by the largest human gene, ... Research conducted at the University of Missouri and described this ... of Sciences has identified significant sections of ... and families. , MU scientists Dongsheng Duan, PhD, and Yi ...
... German . Trees do not grow in ... into oases for deep-sea life - at least temporarily until ... researchers from Germany now showed how sunken wood can develop ... By using underwater robot technology, they confirmed their hypothesis that ...
Cached Biology News:A call to prevent unsafe high-risk medical devices from reaching the marketplace 2A call to prevent unsafe high-risk medical devices from reaching the marketplace 3Scientists discover 'needle in a haystack' for muscular dystrophy patients 2Scientists discover 'needle in a haystack' for muscular dystrophy patients 3Wood on the seafloor -- an oasis for deep-sea life 2
DNA fragmentation factor & Inhibitor of CAD...
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Component in MasterPure™ Purification Kits...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: